No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Inozyme Pharma Shares Are Trading Lower After Multiple Firms Cut Their Respective Price Targets on the Stock.
Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $30
TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating
Inozyme Pharma (INZY) Receives a Buy From TD Cowen
Wells Fargo Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $11
BofA Securities Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $13